Endothelial-to-mesenchymal transition in tumour progression and its potential roles in tumour therapy

Tumour-associated endothelial cells (TECs) are a critical stromal cell type in the tumour microenvironment and play central roles in tumour angiogenesis. Notably, TECs have phenotypic plasticity, as they have the potential to transdifferentiate into cells with a mesenchymal phenotype through a process termed endothelial-to-mesenchymal transition (EndoMT). Many studies have reported that EndoMT influences multiple malignant biological properties of tumours, such as abnormal angiogenesis and tumour metabolism, growth, metastasis and therapeutic resistance. Thus, the value of targeting EndoMT in tumour treatment has received increased attention. In this review, we comprehensively explore the phenomenon of EndoMT in the tumour microenvironment and identify influencing factors and molecular mechanisms responsible for EndoMT induction. Furthermore, the pathological functions of EndoMT in tumour progression and potential therapeutic strategies for targeting EndoMT in tumour treatment are also discussed to highlight the pivotal roles of EndoMT in tumour progression and therapy. KEY MESSAGES This review comprehensively summarizes and discusses the phenotypic plasticity of TECs, the critical influence of EndoMT in tumour progression and therapy and potential EndoMT-targeted therapeutic strategies to highlight and connect the gaps in knowledge and therapeutic opportunities.

Automated summary

Tumour-associated endothelial cells (TECs) are a critical stromal cell type that play important roles in tumour angiogenesis. TECs have the ability to undergo endothelial-to-mesenchymal transition (EndoMT), which influences various malignant properties of tumours, making it a valuable target for tumour treatment. This review comprehensively explores the phenomenon of EndoMT in the tumour microenvironment, identifies the factors and mechanisms responsible for EndoMT induction, and discusses potential therapeutic strategies for targeting EndoMT in tumour treatment.